X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/01/09/2584775/0/en/Santhera-and-ReveraGen-Announce-FDA-Acceptance-of-New-Drug-Application-for-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://endpts.com/penny-stock-forges-ahead-with-an-nda-for-duchenne-treatment/
https://www.globenewswire.com/news-release/2022/10/27/2542398/0/en/Santhera-and-ReveraGen-Complete-NDA-Submission-to-FDA-for-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/10/10/2530644/0/en/Santhera-and-ReveraGen-Announce-Presentations-on-Long-Term-Efficacy-and-Bone-Health-in-DMD-During-Vamorolone-Treatment-at-the-2022-World-Muscle-Society-Congress.html
https://www.globenewswire.com/news-release/2022/08/22/2501855/0/en/Santhera-and-ReveraGen-Announce-First-Participant-Dosed-in-FDA-funded-Phase-2-Pilot-Study-with-Vamorolone-in-Becker-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/06/09/2459298/0/en/Santhera-and-ReveraGen-to-Present-New-Data-with-Vamorolone-at-2022-Parent-Project-Muscular-Dystrophy-Conference.html
https://www.globenewswire.com/news-release/2022/03/29/2411494/0/en/Santhera-and-ReveraGen-Start-Rolling-NDA-Submission-to-the-FDA-for-Vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/03/15/2403031/0/en/Santhera-and-ReveraGen-to-Present-Efficacy-and-Safety-Data-with-Vamorolone-at-2022-Muscular-Dystrophy-Association-Conference.html
https://www.globenewswire.com/news-release/2021/11/23/2339468/0/en/Santhera-and-ReveraGen-Announce-Positive-Topline-Results-with-Vamorolone-after-Completion-of-the-VISION-DMD-Study.html
Market Place
Share 
